Overview

A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis

Status:
Completed

Trial end date:
2013-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the acid-inhibitory and dose-response efficacy of TAK-438 (20 mg, 40 mg) in patients with PPI-resistant erosive esophagitis.

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Treatments:

Proton Pump Inhibitors